作者
Wang-De Hsiao, Cheng-Yuan Peng, Po-Heng Chuang, Hsueh-Chou Lai, Ken-Sheng Cheng, Jen-Wei Chou, Yang-Yuan Chen, Cheng-Ju Yu, Chun-Lung Feng, Wen-Pang Su, Sheng-Hung Chen, Jung-Ta Kao
发表日期
2016/12
期刊
BMC gastroenterology
卷号
16
页码范围
1-9
出版商
BioMed Central
简介
Background
Transarterial chemoembolization (TACE) and sorafenib are the therapeutic standard for intermediate and advanced stage hepatocellular carcinoma (HCC) patients respectively. High costs with adverse events (AE) of sorafenib might limit sorafenib dosage, further affecting therapeutic response. To attain greatest benefit, we evaluated the efficacy of different doses and effect of TACE during and after sorafenib discontinuation in patients representing Child-Pugh Classification Class A with venous or extra-hepatic invasion.
Methods
A total 156 patients met the criteria and were divided into Groups I (n = 52) accepting 800 mg/day; II (n = 58) accepting 800 mg/day and reduced to 400 mg/day owing to AE; and III (n = 46) accepting 400 mg/day. TACE was performed during and after sorafenib discontinuation and therapeutic response …
学术搜索中的文章
WD Hsiao, CY Peng, PH Chuang, HC Lai, KS Cheng… - BMC gastroenterology, 2016